- Angiogenesis inhibitor under investigation in the treatment of high-grade gliomas, pancreatic cancer, and non-small cell lung cancer
THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.
- Available as a 15 mg/mL solution. Each vial contains 500 mg (33.3 mL).
- Store vials in refrigerator without any specific precautions against light exposure. Stable until retest date.
- Undiluted solution is stable for 7 days at room temperature.
- Diluted solution is stable for 72 hours at room temperature diluted in 0.9% NaCl and for 24 hours at room temperature diluted in D5W.
- Solutions Compatible: D5W , NS
Incompatible: DO NOT mix with any other drugs
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
|IV Intermittent Infusion||
|IV Continuous Infusion||NO|
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- ACNS0621: 1800 mg/m2 IV twice weekly (at least 2 days between doses) x 4 weeks. Repeat cycle every 28 days
- Maximum Dose from ACNS0621-75 mg/kg/dose
Immediate (within 1-2 days of receiving drug):
- Common (> 20 %): Fatigue and nausea
- Occasional (5- 20%): anorexia, constipation or diarrhea, xerostomia, dyspepsia, dysgeusia (taste alteration) vomiting, rash/desquamation, shortness of breath, cough, pain (back, chest, head, joint, muscle), headache, somnolence, depressed level of consciousness, insomnia.
- Rare (< 5%): severe bleeding (CNS, dermal, renal, GI), seizures, respiratory failure, thromboembolic events, anaphylaxis (in combination with gemcitabine), increased bleeding time (secondary to transient thrombocyte aggregation).
Prompt (within 2-3 weeks, prior to next cycle):
- Occasional (5- 20%): mucositis/stomatitis, petechiae/purpura, haemoglobin, ¯ WBC, lymphopenia, thrombocytopenia, ALT/AST alk phos, hyperglycemia, hypophosphatemia, hypokalemia, hyponatremia.
- Rare (< 5%): DVT and DVT with PE (in combination with temozolomide), intratumoral hemorrhage.
- Occasional (5- 20%): Neuropathy
Unknown frequency and timing
- Fetal and teratogenic toxicities
Treatment of unusual side effects is available through the study chair identified on the front page of the protocol and/or pharmacy.
- Mechanism of action: avß3 and avß5 integrin receptor antagonist.
- Predominantly excreted unchanged in urine.
- Has not been found to inhibit main cytochrome P450 enzymes.
- Administration (if peripheral) through a new peripheral intravenous catheter is recommended
- Administer through a 0.22 micron in-line filter